Advanced Search:

CORT - Corcept Therapeutics Incorporated

$22.92  -0.26 (-1.12%)

Updated: 16:58 Nov 24, 2021 EST

Equity Rank Position

Overall Rank Position

Innrs Rank

Now

27.65

This Week

34.25

This Qtr.

28.49

Next Qtr.

34.26

This Year

41.84

Corcept Therapeutics Incorporated's Position Within the Biotechnology Industry
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)

CORCEPT THERAPEUTICS INCORPORATED - HISTORICAL DATA 6M

  • Last price

    $ 22.92

  • Daily change

    $ -0.26

  • Previous Close

    $ 23.18

  • Last Updated

    16:58 Nov 24, 2021 EST

CURRENT VOLATILITY

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
-0.86 1.18 0.11 0.04 -0.01

CURRENT VOLATILITY RANK

Variation from the lowest to the highest value in a period.

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
2.92 2.39 1.81 1.55 1.56

STOCHASTIC METRIC

The STOCHASTIC METRIC shows when a financial asset has moved into an overbought or oversold position.

OVERSOLD
OVERBOUGHT
Curr. Week Next Week Curr. Month Curr. Quarter
0% 0% 84.77% 85.22%

MOVING AVERAGE METRIC

5 Sessions Change 5 Sessions 20 Sessions Change 20 Sessions 50 Sessions Change 50 Sessions 200 Sessions
22.34 14.21% 19.56 -1.01% 19.76 -5.68% 20.95

RSI METRIC

RS Hour RSI Hour RS Day RSI Day
1.34 33.33 3 57.26

Corcept Therapeutics Incorporated

149 Commonwealth Drive
Menlo Park, CA 94025
United States
650 327 3270
http://www.corcept.com

Sectors: Healthcare
Industry: Biotechnology
F. Time Employees: 236
Description

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with serous ovarian tumors, as well as in Phase III clinical trial for the treatment of solid tumors. The company is also developing selective cortisol modulator combined with Xtandi that is in open label dose finding trial to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.

Corporate Governance

Corcept Therapeutics Incorporated’s ISS Governance QualityScore as of September 26, 2021 is 8. The pillar scores are Audit: 10; Board: 5; Shareholder Rights: 7; Compensation: 9.

CORCEPT THERAPEUTICS INCORPORATED'S HOLDERS RANK

List of holders with stock participation in Corcept Therapeutics Incorporated.